•United Therapeutics announced that its experimental pill for a blood pressure disorder met all primary and secondary goals in a late-stage clinical study.
•The Centers for Medicare & Medicaid Services (CMS) plans to suspend enrollment of beneficiaries into certain Medicare Advantage plans operated by Elevance Health.
•Elevance Health stock experienced a decline following the announcement of the enrollment halt.
•EyePoint Pharmaceuticals has dosed the first patients in two global Phase 3 clinical trials of DURAVYU for the treatment of Diabetic Macular Edema (DME).
•DURAVYU targets multi-billion-dollar retinal disease markets, including wet AMD and DME.